This study is in progress, not accepting new patients
A Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn's Disease
Summary
- Eligibility
- for people ages 18-75 (full criteria)
- Location
- at UCSD UCSF
- Dates
- study startedcompletion around
- Principal Investigator
- by Jonathan Terdiman (ucsf)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Jonathan Terdiman (ucsf)
Dr. Jonathan P. Terdiman is a Professor of Clinical Medicine and Surgery and the Chief of the Gastroenterology Division at UCSF Health. He earned his undergraduate degree from Princeton University in 1985 and his medical degree from the Columbia University College of Physicians and Surgeons in 1989.
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- AbbVie
- Links
- This clinical study may be evaluating a usage that is not currently FDA approved. Please see US Prescribing Information for approved uses.
- ID
- NCT02782663
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- About 107 people participating
- Last Updated